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Objective: In breast cancer, several tumor markers have been identified. The marker most 
extensively associated with breast cancer is MUC1. The objective of the study was to analyze 
prognostic and risk factors in relation to tumor markers in order to clarify breast cancer biology. 
A total of 349 primary tumor samples and lymph nodes from breast cancer patients were studied. 
Risk and prognostic factors were considered. An immunohistochemical approach was applied 
and an extensive statistical analysis was performed, including frequency analysis and analysis 
of variance. Correlation among variables was performed with principal component analysis.
Results: All the antigens showed an increased expression according to tumor size increment; 
moreover, sialyl Lewis x expression showed a significant increase in relation to disease stage, 
whereas Tn and TF presented a positive tendency. Vascular invasion was related to sialyl 
Lewis x expression and number of metastatic lymph nodes. Taking into account risk factors, 
when a patient had at least one child, Lewis antigens diminished their expression. In relation to 
breastfeeding, sialyl Lewis x expression diminished, although its apical expression increased.
Conclusion: Associations between MUC1 and carbohydrate antigens and risk and prognostic 
factors show the complexity of the cellular biological behavior that these antigens modulate 
in breast cancer.
Keywords: breast cancer, Argentine women, risk factors, prognostic factors, antigenic 
expression
Introduction
In Argentina, it has been estimated that 17,000 new cases of breast cancer are diagnosed 
each year. This tumor localization is the commonest cause of cancer death in women, 
reaching 5400 deaths per year,1 which is the second rate of mortality in Latin America.1 
Although there is a strong public health system that covers all the expenditure in relation 
to cancer treatments, disadvantaged groups have high mortality rates, probably because 
of a lack of preventive actions.
Because MUC1 has been shown to be overexpressed and aberrantly glycosylated 
in breast and other carcinomas, in this report we studied this mucin and carbohydrate 
associate antigens.
MUC1 is a high molecular transmembrane glycoprotein expressed as a stable 
heterodimer after translation of a single polypeptide and cleavage into two subunits in 
the endoplasmic reticulum.2 The MUC1 N-terminal subunit contains variable numbers 
of 20 amino acid tandem repeats that are extensively modified by O-linked glycans.3 
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The MUC1 C-terminal subunit consists of a 58 amino acid 
extracellular domain, a 28 amino acid transmembrane 
domain, and a 72 amino acid cytoplasmic chain.4
MUC1 expression in normal epithelia can be quite 
dynamic, varying in response to steroid hormone or cytokine 
influences.5 Following malignant transformation, MUC1 
often becomes highly overexpressed, loses its apical polariza-
tion, and displays aberrant glycosylation as well as altered 
mRNA splicing variants.6 In addition, post-translational 
regulation of cell surface expression occurs via the activity 
of cell surface proteases that release soluble forms of MUC1 
large ectodomain. In cancer, mucin O-glycosylation is char-
acterized by aberrant expression of immature carbohydrate 
structures such as Tn, T, and sialyl Tn antigens7 and Lewis 
blood group antigens (Lewis x, Lewis y, Lewis b, Lewis a, 
and their sialylated derivatives).8
Some reproductive factors, including age at menarche, 
age at first full-term pregnancy, number of live births, and 
breastfeeding, have been related to risk of breast cancer,9 
because their impact on lifetime number of ovulatory 
cycles modifies exposure to endogenous ovarian hormones.8 
Additionally, both pregnancy and breastfeeding induce the 
differentiation of breast epithelial cells, making them less 
susceptible to carcinogenic insults.10
MUC1 expression in breast tissue increases during preg-
nancy and lactation;11 also, MUC1 serum levels augment 
according to pregnancy development.12,13 In relation to this, 
it has been hypothesized that, during pregnancy, MUC1 may 
stimulate the immune system, which may play a protective 
role against breast cancer.14 MUC1 has been detected to be 
bound to immunoglobulins (Igs), forming circulating immune 
complexes (MUC1CIC) in pregnant women.15
Many authors have described associations between MUC1 
expression and prognostic factors in breast cancer. In general, 
a significant positive correlation has been found between 
estrogen receptor (ER) status and MUC1 expression.16 At the 
same time, between increased MUC1staining and histological 
grade, a significant, inverse relationship was detected,16–18 as 
well as with a nuclear grade.19
This study selected MUC1 and glycan epitopes to ascer-
tain their associations with different risk and prognostic 
factors in breast carcinoma in Argentine women.
Materials and methods
Patients and tumors
From January 2007 to December 2010, 349 patients under-
went surgery for invasive breast carcinoma at institutions 
related to the Faculty of Medical Sciences of the National 
University of La Plata, La Plata, Argentina. All these 
patients were included in the present study. Primary tumor 
samples were obtained and typed as 81% not  otherwise 
specified ductal type (NOS ductal), 16% lobular type (L), 
and 3% medular type. Tumors corresponding to NOS 
ductal presented different grades of differentiation: 17.2% 
were well differentiated, 55.2% moderately differenti-
ated, and 27.6% poorly differentiated. Staging according 
to the Union for International Cancer Control’s TNM 
classification system was established: 105 of 349 (30%) 
corresponded to Stage I, 142 of 349 (41%) to Stage II, 
87 of 349 (25%) to Stage III, and 15 of 349 (4.3%) to 
Stage IV. In some cases, metastatic lymphatic nodes were 
also obtained.
Patients’ clinical data and cancer characteristics included 
some risk and prognostic factors. Risk factors were age at 
diagnosis (56 ± 14, range 29–85 years); age at menarche 
(12.9 ± 1.5, range 10–16 years); menopausal status: pre-
menopausal included 43% of patients while postmenopausal, 
57%; breastfeeding: positive 51.7% and negative 48.3%; and 
children: positive 74.3% and negative 25.7%. Prognostic 
factors included disease stage; axillary nodal status: nega-
tive (1) 38.7% of patients, positive: # 3 (2) 84.6% while .3 
(3) 15.4%, not assessed: 1.9% of patients; tumor size: T1 
38.1% of patients, T2 54.3%, and T3 7.6%; histological 
differentiation: I 31.5%, II 45.7%, and III 22.8%; nuclear 
grade: Grade 1 32.7%, Grade 2 40.4%, and Grade 3 26.9%; 
mitotic figure counts; Nottingham Prognostic Grade:20 
good (I) 44.6%, moderate (II) 42.9%, and poor (III) 12.5%; 
vascular invasion: positive 29.8% and negative 70.2%; ER 
status: positive 66.7%, negative 18.1%, unknown 15.2%; and 
progesterone receptor (PR) status: positive 63.8%, negative 
18.1%, unknown 18.1%.
Controls
A total of 148 tissue samples belonging to patients with 
benign breast disease (BBD) and normals were included. 
BBDs were classified as follows: (1) simple fibroadenoma 
(FA), (2) nonproliferative lesions (NPF) comprised fibrocys-
tic changes/apocrine metaplasia and fibrosis, (3) proliferative 
lesions without atypia (usual epithelial hyperplasia [UEH]), 
and (4) proliferative lesions of ductal type with atypial ductal 
hyperplasia (ADH).
A total of 116 samples corresponded to BBD being 50 FA, 
28 NPF, 30 UEH, and eight ADH. Also, 32 normal specimens 
obtained during breast cosmetic surgery were included. The 
mean age of patients with BBD and normal females was 
42.2 ± 13.6 years.
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Procedures followed the World Medical  Association 
 Declaration of Helsinki (Finland, 1964) and further 
 modifications. Informed consent was obtained from all 
patients included in this study. This research was approved 
by the local Human Investigation Committee, Faculty of 
Medical Sciences, National University of La Plata.
Tumors and tissues were collected fresh and delivered 
to the laboratory with minimal delay. For histopathological 
diagnosis and immunohistochemical analysis, a sample frac-
tion was fixed in methacarn (methanol: chloroform: acetic 
acid 60:30:10) for 2 hours and transferred into 70% ethanol 
until processing in paraffin.
Monoclonal antibodies (Table 1)
Three anti-MUC1 variable number of tandem repeats (VNTR) 
monoclonal antibodies (MAbs) were assayed: HMFG1,21 
C595,22 and SM3.11 Also, five anticarbohydrate epitopes: 
anti-sialyl Lewis x (KM93),23 anti-Lewis x (KM380),23 anti-
Lewis y (C14),24 anti-Tn Mabs, and anti-TF MAbs (DAKO, 
Copenhagen, Denmark) were used in these studies.
Methods
Immunohistochemical analysis
The technique was performed following previous reports.25 
Dewaxed sections were placed in methanol with hydrogen 
peroxide (3%) for 15 minutes to block endogenous per-
oxidase activity. After three washes in phosphate buffered 
saline (PBS), sections were blocked for nonspecific binding 
with normal horse serum diluted 1:10 in 1% bovine serum 
albumin/PBS for 15 minutes and rinsed. Before samples were 
immunostained with MAbs, tissues were treated with 10 mM 
sodium citrate buffer at 100°C for 5 minutes for antigenic 
retrieval. Then, sections were incubated overnight at 4°C with 
MAbs, which were diluted as follows: C595, KM93, KM380, 
and C14, 1/1000; anti-Tn; and TF 1/100. HMFG1 and SM3 
were not diluted (tissue culture supernatants). After three 
washes with PBS, peroxidase-conjugated antimouse Igs 
(Sigma-Aldrich Co, St Louis, MO) were added and incubated 
for 60 minutes. After being washed, slides were counter-
stained with hematoxylin and coverslipped with mounting 
media. In every assay, we included a positive control sample, 
and the same tissue section was incubated with PBS instead 
of the primary Ab as a negative control.
Specimens were examined with a light microscope and 
the antibody staining patterns were scored in a semiquantita-
tive manner. Staining intensity was graded as negative, low, 
moderate, and strong. The number of low power ( × 10) optical 
fields in a specimen with a positive reaction was expressed 
as a percentage of the total number of optical fields contain-
ing tissue. The pattern of reaction was classified as linear 
(membrane), cytoplasmic, and mixed pattern (cytoplasmic 
with plasma membrane staining), and apical and nonapical 
staining was recorded.25 The positive reaction of the nucleus 
was considered, as well as the staining of gland lumen content, 
which was identified as cellular debris or secretion.
Statistical analysis
Patients were grouped, taking into account risk and prognos-
tic factors, and positive responses were evaluated by means 
of frequency analysis (χ2 test, P , 0.05).
A reactivity index (RI) was calculated as intensity (I) × 
100 + percentage of positive area (A).26
Normality of variables was tested by Shapiro Wilk’s, and 
data were normalized when necessary.
Correlation among variables was performed with prin-
cipal component analysis (PCA). Immunohistochemical 
pattern, percentage of positive area, and RI were analyzed 
employing analysis of variance (P , 0.05) after data 
standardization.
Also, logistic regression analysis was performed. In this 
sense, a multiple logistic regression analysis was conducted, 
subgrouping breast cancer patients according to ER, PR, 
Table 1 Antibodies assayed
Antigen Epitope structure MAb Isotype and source Reference
MUC1VNTR Pro-Asp-Thr-Arg hMFG1 IgG1 – mouse MAb Taylor-Papadimitriou J et al21
MUC1VNTR Arg-Pro-Ala-Pro C595 IgG3 – mouse MAb Price et al22
MUC1 VNTR Pro-Asp-Thr-Arg-Pro SM3 IgG1 Burchell et al11
Sialyl Lewis x NeuAc2-3Galβ1-4GlcNAcβ1-3Gal-R KM93 IgM – mouse MAb hanai et al23
Lewis x Galβ1-4GlcNAcβ1-3Gal-R KM380 IgM – mouse MAb hanai et al23
Lewis y Gal(α1-2Fuc)β1-4GlcNAc(α1-3Fuc) 
β1-3Gal-R
C14 IgM – mouse MAb Brown et al24
Tn GalNAcα-R Anti-Tn IgM – mouse MAb Dakoa
Thomsen-Friedenreich Galβ1-3GalNAcα1-R Anti-TF IgM – mouse MAb Dakoa
Notes: aDakopatts, Dako Corporation, Copenhagen, Denmark.
Abbreviations: Ig, immunoglobulin; MAb, monoclonal antibody.
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and Her2-neu positive-negative responses using patients’ 
prognostic and risk factors as independent variables. Missing 
data cases were deleted (minimum n = 332).
Results
Immunohistochemical reactivity of the different antigens 
assayed obtained in malignant samples according to disease 
stage are summarized in Table 2; results obtained in control 
samples (benign and normal) are also included. Results are 
expressed as percentage of positive samples in respect of 
the total.
Table 3 shows antigenic expression results of normal 
breast, BBD, and breast cancer samples expressed as RI.
Breast cancer
MUC1 expression in primary tumor samples
MUC1 expression was detected employing three anti-MUC1 
VNTR MAbs. Most samples were stained with at least one 
anti-MUC1 MAb; the most reactive was HMFG1 MAb, 
because 92.7% of samples were positive, whereas C595 MAb 
reacted with 61.4% of samples and SM3 MAb with 39.5% 
of samples.
As has been previously observed,17,18,27 the cellular local-
ization as well as the intensity of the staining varied among 
specimens. Most samples showed a nonapical, cytoplasmic 
pattern with a strong staining (Figure 1A, B, and C), and 
several samples showed an apical pattern with a linear, 
cytoplasmic, or mixed reaction.
Carbohydrate antigenic expression  
in primary tumor samples
Seventy-three percent of samples expressed at least one 
glycan antigen. Lewis x was the most frequently found, 
and 50.7% of tumors showed reactivity with either a linear 
or a mixed staining, mainly restricted to the apical part 
of the ductal cells. In most cases, a strong reaction was 
detected.
In respect of sialyl Lewis x, it was found that 27.5% of 
samples were reactive. Staining was mainly linear and apical, 
although some samples depicted a cytoplasmic nonapical 
reaction (Figure 1D). Twenty-six percent of specimens were 
positive for Lewis y, showing different patterns of staining: 
linear and apical in some samples and cytoplasmic and 
nonapical in some others, whereas several specimens showed 
a mixed and apical or even nonapical staining. Tn hapten was 
detected in 29.6% of specimens. Reaction was mainly found 
in a few cells. In some tumors, expression was  cytoplasmic, 
whereas others stained the plasmatic membranes, usually 
Table 2 Percentage of positive immunohistochemical results obtained in normal, benign, and cancer breast samples
Specimens Anti-VNTR MUC1 Anti-carbohydrate antigens MAbs
C595 HMFG1 SM3 Lewis x sialyl Lewis x Lewis y Tn TF
Normal 40 100 5 46 10 7 2 0
FA 57 92 0 50 12 3 21 2
NPF 58 100 2 58 15 25 10 3
UEh 56 100 16 92 24 28 36 14
ADh 57 ND 14 71 14 43 14 29
I 63 92 40 54 24 22 25 3
II 59 92 38 57 25 31 31 22
III 58 93 41 44 35 20 35 28
IV 86 98 47 60 33 40 20 49
Abbreviations: ADH, atypial ductal hyperplasia; FA, fibroadenoma; MAbs, monoclonal antibodies; NFP, nonproliferative lesions, UEH, usual epithelial hyperplasia; VNTR, 
variable number of tandem repeats.
Table 3 Antigenic expression of normal breast, BBD, and breast cancer samples expressed as reactivity indexes
Antigen Normal samples BBD samples Breast cancer
MUC1 (hMFG1MAb) 110 ± 164 162 ± 162 376 ± 112
MUC1 (C595 MAb) 125 ± 155 185 ± 174 299 ± 101
MUC1 (SM3 MAb) 20 ± 70 17+/68 261 ± 146
Sialyl Lewis x 27 ± 65 50 ± 110 219 ± 109
Lewis x 181 ± 133 234 ± 155 307 ± 77
Lewis y 24 ± 68 84 ± 127 269 ± 65
Tn 12 ± 62 46 ± 92 277 ± 118
TF 0 19 ± 66 223 ± 129
Abbreviations: BBD, benign breast disease; MAb, monoclonal antibody.
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with a mild reaction. Finally, TF was found in 25% of 
samples with either linear or apical (Figure 1E) or mixed 
nonapical patterns.
Antigenic expression in metastatic 
lymphatic nodes
In a group of 20 patients, a metastatic node sample was 
analyzed. Fifty percent of lymphatic nodes were positive for 
MUC1. In these samples, metastatic malignant cells showed a 
cytoplasmic staining with a strong intensity (Figure 1F). The 
most reactive anti-MUC1 MAb was HMFG1. Sialyl Lewis x 
showed reactivity in eight of 20 samples (Figure 1G) and 
Lewis x in six of 20 samples with the same pattern. Lewis y, 
Tn, and TF (Figure 1H) were detected in four of 20 samples 
with a cytoplamic reaction and low intensity.
Correlation among antigens
Sialyl Lewis x showed a positive correlation with Tn antigen 
(r = 0.8147; P , 0.034), whereas Lewis x and Lewis y showed 
a strong and positive correlation (r = 0.92; P , 0.016).
A positive tendency between MUC1 and Lewis x 
apical expression was detected. Taking into account 
the RI, a positive correlation between MUC1 (detected 
with SM3 MAb) versus Lewis x was found (r = 0.8830; 
P , 0.022).
Relationship between MUC1 expression 
and prognostic factors
MUC1 detection with the three different anti-MUC1 MAbs 
(HMFG1, C595, and SM3) showed some differences when 
they were correlated with prognostic factors.
In order to analyze in more depth the antigenic expres-
sion, RI was calculated as intensity (I) × 100 + percentage of 
positive area (A).26 According to anti-MUC1 MAb in relation 
to disease stage, for HMFG1, MAb RI and Stage I results 
were 355 ± 155, Stage II 386 ± 113, Stage III 389 ± 98, and 
Stage IV 480 ± 71. A raise tendency was detected but with 
no statistical significance (Tukey HSD; P = 0.067) (Figure 3). 
For C595, MAb and Stage I results were 299 ± 110, Stage II 
287 ± 109, Stage III 311 ± 84, and Stage IV 289 ± 122. 
Finally, for SM3, MAb and Stage I results were 281 ± 156, 
Stage II 267 ± 137, Stage III 236 ± 147, and Stage IV 
272 ± 112.
Percentage of positive responses detected with all MAbs 
increased according to tumor size increment (Figure 2), 
with statistically significant C595 and SM3 MAbs reactivity 
(P , 0.040).
It was not possible to find a relationship between the pat-
tern of expression of MUC1 and disease stages.
Furthermore, MUC1 apical expression frequency 
detected with HMFG1 MAb showed a significant decrease 
according to histological grade increment (P , 0.031) 
(Figure 3). The percentage of samples with apical expression 
for Grade 1 tumors was 37.5%, for Grade 2 tumors 
was 25.5%, and for Grade 3 tumors was 16.7%; a similar 
observation was found with nuclear Grade I 41%, Grade II 
19%, and Grade III 16%.
Finally, considering the percentage of MUC1 reactive 
area, tumors that presented a high percentage showed a low 
nuclear grade.
Figure 1 Photomicrographs of immunoperoxidase staining of primary ductal breast 
carcinoma samples (A–E) are shown. Staining with anti-MUC1 hMFG1 monoclonal 
antibodies (MAbs) (A), a mixed nonapical pattern of reaction with a strong intensity 
is observed; (B) a mixed reaction is shown (note the strong apical pattern); 
(C) staining with anti-MUC1 C595 MAb, a cytoplasmic and moderate reaction is 
depicted; (D) reaction obtained with anti-sialyl Lewis x MAb, a mixed reaction is 
shown; lumen content appears strongly stained; (E) the TF antigenic reaction shows 
a linear and apical pattern. Immunohistochemical reactions of metastatic lymphatic 
nodes (F–H) are depicted: (F) staining with anti-MUC1 hMFG1 MAb, a strong 
cytoplasmic reaction is shown; (G) the sialyl Lewis x cytoplasmic reaction is 
clearly visible in many metastatic cells and (H) staining obtained with anti-TF 
MAb, a cytoplasmic strong reaction is shown.
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A significant mild correlation was found between MUC1 
RI detected with HMFG1 MAb and ER (r = 0.23609, 
P , 0.033), whereas with PR status a similar, though not 
significant, tendency was observed.
Relationship between carbohydrate 
antigenic expression and prognostic 
factors
TF percentage of positive samples increased with disease 
stage; sialyl Lewis x as well as Tn expression also aug-
mented with disease stage, although Stage IV showed a 
decrease, whereas Lewis y and Lewis x did not vary with 
stage (Table 2).
Stage I patients showed a lower percentage of sialyl 
Lewis x, Lewis y, and TF reactive area in respect of the 
other stages (P , 0.011). On the contrary, Lewis x showed 
a higher percentage of reactive area in Stage I patients and 
also in more differentiated tumors (P , 0.045).
Considering RIs, sialyl Lewis x and TF RIs increased 
with disease stage (Figure 4A and B, respectively),  showing 
a  positive tendency, whereas Tn RI augmented with the 
presence of metastatic nodes, histological grade, and 
mitotic index.
The percentage of glycan-positive responses increased 
according to tumor size increment, being statistically signifi-
cant for Tn and Lewis y antigens (Figure 2) (P , 0.0043).
Vascular invasion and antigenic 
expression
Ejlertsen et al28 defined low-risk patients as those patients 
who were older than 35 years at diagnosis, with LN-negative 
disease, tumor size # 2 cm, low or moderate histologic grade, 
and positive hormonal status. Taking into account this clas-
sification, in our study most of the low-risk patients (87%) 
did not present vascular invasion (VI), whereas MUC1 apical 
expression was found in 25% of them and VI-positive tumors 
did not show MUC1 apical reaction.
Percentage of positive MUC1 tumor area was higher in 
VI-negative tumors than in positive ones, being statistically 
significant when MUC1 was measured with C595 MAb.
0%
HMFG1C595 SM3
1 = well
2 = moderate
3 = poor
20%
10%
30%
40%
50%
60%
70%
F
re
q
u
en
cy
Figure 3 Apical expression frequencies of anti-MUC1 monoclonal antibodies according to histological grade. In all cases, apical expression decreases when histological 
differentiation grades increase.
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20%
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Figure 2 Relative percentage frequencies of staining obtained with the different anticarbohydrate antigens and MUC1 monoclonal antibodies according to tumor size. In all 
cases, a rising tendency is observed.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
166
Demichelis et al
 
Br
ea
st
 C
an
ce
r: 
Ta
rg
et
s 
an
d 
Th
er
ap
y 
do
w
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
16
3.
10
.3
4.
20
4 
on
 2
7-
Au
g-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Breast Cancer:  Targets and Therapy 2011:3
Furthermore, poorly differentiated tumors had higher 
rates of VI than well and moderately differentiated tumors 
(P , 0.0012); in large tumors, VI was detected more 
frequently. VI was significantly higher in patients aged 
, 50 years than in those aged . 50 years (P , 0.036).
Positive tumors for sialyl Lewis x showed more VI than 
negative ones: 23% versus 12% (P , 0.0073). Employing 
frequency analysis it was possible to demonstrate an associa-
tion between sialyl Lewis x expression and the number of 
metastatic lymph nodes. This analysis showed that patients 
with sialyl Lewis x reactive primary tumors presented an 
increment of the frequency on the number of metastatic 
lymph nodes (P , 0.0249). Finally, a positive relationship 
between VI and Nottingham Prognostic Index was demon-
strated (P , 0.033).
Relationship among risk factors  
and antigenic expression
In relation to the number of children and breastfeeding, 
the percentage of positive tumor samples in respect of 
the total showed some variations. When a patient had at 
least one child, a significant increment on MUC1 reactive 
area (P , 0.037) and MUC1 expression increased sig-
nificantly from 75% to 92% (P , 0.021). On the contrary, 
Lewis antigens diminished their expression in patients 
who had children, being significant for sialyl Lewis x 
(from 46% to 27%, P , 0.05) and Lewis y (from 43% to 
22%, P , 0.025). Considering the percentage of MUC1 
(detected with HMFG1) reactive area and breastfeeding, 
a significant increment was found in patients who had 
breastfed (P , 0.018). Although no differences were found 
between breastfeeding and frequency of positive response, 
when RI was considered; C595MAb showed a positive ten-
dency, whereas Lewis x showed a low expression in those 
patients who had lactated.
In respect of sialyl Lewis x, although its expression 
decreased according to increase on breastfeeding, its api-
cal expression showed a positive tendency with lactation, 
whereas Tn and TF antigens showed an increment on apical 
expression in relation to breastfeeding and number of chil-
dren (P , 0.018).
ER, PR, and her2-neu subgroups
In addition, patients were classified according to hormone 
receptor status (ER and PR) and Her2-neu expression, and 
analysis in relation to risk and prognostic factors (Table 4) 
was performed.
Number of positive nodes, tumor size, tumor differentiation, 
and nuclear grade showed significant differences between 
ER-positive versus ER-negative subgroups and also between 
PR-positive versus PR-negative status, whereas age and 
number of mitotic counts showed significant differences only 
between ER-positive and -negative subgroups. Furthermore, 
Her2-neu-positive and Her2-neu-negative patients showed 
significant differences with number of positive lymph nodes, 
tumor differentiation, and nuclear grade.
Multivariate analysis
A multivariate comparative study by PCA was performed, 
taking into account RI values and risk and prognostic factors 
(Figure 5). RI corresponding to MUC1 detected with HMFG1 
and SM3 MAbs and also to anti-sialyl Lewis x, Lewis x, 
Lewis y, Tn, and TF explained 59% of data variability.
When the age was considered, a clear tendency of patients 
aged ,44 years to be grouped was observed in PC1(−) and 
PC2(±) patients, whereas patients aged between 44 years 
and 70 years showed a spread distribution mainly in PC1(+) 
and elderly patients (.70 years old) and remained exclu-
sively in PC1(+) and PC2(−) patients. A similar tendency was 
observed when menopause status was analyzed. In general, 
premenopause patients showed less differentiated tumors. In 
these patients, C595 and HMFG1 anti-MUC1 MAbs showed 
a very high correlation, HMFG1 being the variable that makes 
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Figure 4 Reactivity index according to disease stage. An increasing reactivity is 
observed in higher stages: (A) results obtained with anti-sialyl Lewis x monoclonal 
antibodies (MAbs) and (B) anti-TF MAbs.
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Table 4 Logistic regression analysis for patients grouped according to ER, PR, and her2-neu expression considering risk and prognostic 
factors
Risk and prognostic factors Patient subgoups
ER 
P; OR 
(ORR CL)
PR 
P; OR 
(ORR CL)
Her2-neu 
P; OR 
(ORR CL)
Age (years) 0.017; 3.53 
(0.916–12.5)a
0.094; 2.01 
(0.070–6.35)
0.921; 0.257 
(0.086–1.09)
Number of children 0.224; 1.76 
(0.080–1.88)
0.726; 0.527 
(0.071–6.35)
0.123;1.43 
(0.471–11.2)
Breastfeeding 0.573; 0.415 
(0.095–3.68)
0.995; 0.549 
(0.375–2.65)
0.848;0.63 
(0.031–3.16)
Menopausal age (years) 0.099; 1.31 
(0.008–1.531)
0.007; 0.126 
(0.035–0.416)a
0.951; 0.890 
(0.071–8.25)
Menarche age (years) 0.685; 0.161 
(0.177–13.8)
0.897; 1.13 
(0.122–6.34)
0.927; 0.458 
(0.066–1.98)
Disease stage 0.214; 1.531 
(0.700–1.69)
0.901; 0.849 
(0.279–4.24)
0.454; 2.10 
(0.028–5.06)
Number of positive lymph nodes 0.002; 0.157 
(0.047–0.519)a
0.016; 0.219 
(0.064–0.750)a
0.002; 15.49 
(2.78–86.1)a
Tumor size 0.004; 0.309 
(0.138–0.688)a
0.008; 0.349 
(0.159–0.764)a
0.210;1.89 
(0.695–5.19)
Tumor differentiation 0,000; 0.274 
(0.143–0.525)a
0.001; 0.338 
(0.181–0.633)a
0.042; 2.95 
(1.04–8.36)a
Nuclear grade 0.000; 0.237 
(0.120–0.467)a
0.001; 0.353 
(0.187–0.665)a
0.000; 7.83 
(1.04–8.36)a
Number of mitotic counts 0.004; 0.093 
(0.019–0.462)a
0.156; 0.320 
(0.066–1.55)
0.434;2.75 
(0.216–34.9)
Vascular invasion 0.890; 0.964 
(0.571–1.63)
0.359; 0,790 
(0.477–1.308)
0.161; 1.70 
(0.808–3.59)
Note: aIndicates significant regression P , 0.05.
Abbreviations: ER, estrogen receptor; OR, odds ratio; ORR CL, odds ratio range confidence level for ± 95% range; PR, progesterone receptor.
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Figure 5 Principal component analysis of reactivity indexes. Length of rays shows variable weights. Points represent each sample data. Patients aged ,44 years appear 
grouped on the left of the graphic PC1(−), whereas middle-age groups remain mainly spread in PC2(+). Postmenopause and elder patient groups predominate on the right 
of the graphic (PC1(+),PC2(+) and PC1(+),PC2(−), respectively); I, II, and III indicate histological grades.
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the highest contribution; as a consequence, RI obtained with 
C595 MAb was excluded in the final analysis.
PCA analysis including RI of MUC1 and glycan antigenic 
expression and also ER and PR separated a group of patients 
who were characterized by their low age, premenopause 
status, less differentiated tumors, and negative ER and PR 
status, PC1(−) and PC2(−).
Employing logistic regression analysis we compared 
Stage I versus advanced stages using independent vari-
ables risk factors. Significant regressions were not found 
(Table 5).
Benign breast diseases
Positive results obtained are summarized in Table 2 and 
depicted in Figure 6A–D. In general, a decrease tendency 
of positive expression was found from ADH and UEH to 
NPF and FA specimens.
Anti-MUC1 C595 and SM3 MAbs exhibited a very 
similar pattern of reaction. Apical and linear staining was 
mainly found.
Lewis x epitope and sialyl Lewis x were expressed at 
apical membranes and cytoplasm. The luminal content was 
stained. Although the former was found very frequently, 
the latter was expressed in a low percentage of specimens. 
Lewis y showed a cytoplasmic mild reaction in several 
samples, whereas Tn was reactive in only a few cells in some 
sections. TF was expressed with either a linear or cytoplasmic 
pattern, mainly apical and restricted to some areas.
Normal samples
MUC1 showed a moderate to strong expression. In most 
samples, an apical pattern mainly restricted to the plasma 
membrane was found (Figure 6E–F). Lumen content was 
also stained. Lewis x was expressed with a high intensity in the 
apical part of cell ducts; this pattern was found in all posi-
tive samples. Sialyl Lewis x (Figure 6G), Lewis y, and Tn 
epitopes were detected at the cytoplamic level and with a 
low intensity, whereas TF was not detected in any sample 
(Figure 6H).
To compare risk factors between normal group and 
malignant patients and also between benign versus malignant 
patients, a logistic regression analysis was performed. Results 
are summarized in Table 6; significant differences were found 
only between normal and malignant ages.
In our research, in BBD and normal women, risk factors 
such as age of menarche, parity, and breastfeeding, were simi-
lar to those for breast cancer patients. Significant differences 
were found between normal and malignant ages (Table 5). 
Table 5 Logistic regression analysis for patients grouped according 
to disease stage using Stage I as a reference and considering risk 
factors
Risk and prognostic factors Stage I vs advanced stages
Age (years) 0.077; 0.396 
(0.142–1.10)
Number of children 0.056; 3.71 
(0.963–14.4)
Breastfeeding 0.363; 2.70 
(0.314–23.5)
Menopausal age (years) 0.102; 0.261 
(0.052–1.31)
Menarche age (years) 0.441; 1.47 
(0.545–3.99)
Figure 6 Photomicrographs of immunoperoxidase staining of benign breast 
diseases (A–D) and normal (E–H) are shown. Staining with anti-MUC1 
hMFG1 monoclonal antibody (MAb), (A) an apical pattern of reaction with a strong 
intensity is observed in a non proliferative lesion; (E) normal mammary ducts are 
shown with an apical reactivity. Staining with anti-MUC1 C595 MAb, (B) a sample 
of an apocrine metaplasia is depicted; an apical mainly linear reaction is observed; 
(F) normal mammary gland sample showing a linear apical reaction. Expression 
of sialyl Lewis x (C) a strong linear staining in a fibroadenoma sample is shown 
and (G) a negative normal mammary gland sample is depicted. The TF antigenic 
reaction in (D) a fibroadenoma specimen is shown with a linear and apical pattern 
and in a (H) normal negative sample.
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than well and moderately differentiated tumors (P , 0.005). 
In large tumors, vascular invasion was detected more 
frequently.
Some authors argue that the glycosylation pattern of 
MUC1 expressed by normal mammary epithelium is based 
on elongated Core 2 structures, whereas in breast carcino-
mas the glycans expressed on MUC1 are often shorter and 
Core 1 based.31 In contrast, Müller and Hanisch32 found that 
no general pattern could be regarded as breast cancer asso-
ciated and demonstrated a preponderance of Core 2-based 
structures. These structures have been associated with sialyl 
Lewis x determinant,33 which acts as a ligand for binding 
carcinoma cells to endothelium in different tumor localiza-
tions, including breast cancer.34,35 In this sense, we found that 
tumors with sialyl Lewis x expression frequently showed 
more vascular invasion. This parameter was evaluated by 
conventional histological assessment, which is considered an 
adequate method of examination.36 Furthermore, we found 
that patients whose tumors expressed more sialyl Lewis x 
had a large number of metastatic lymph nodes (P , 0.01) 
and that patients with sialyl Lewis x reactive primary tumors 
presented an increment of the frequency on the number of 
metastatic lymph nodes (P . 0.05). However, we found 
that sialyl Lewis x expression was reduced in lymph nodes 
compared with the primary tumor. This finding coincides 
with that of Jeschke et al.37
In a study that comprised more than 16,000 patients, 
Ejlertsen et al28 defined low-risk patients as those patients 
who were older than 35 years at diagnosis, with LN-negative 
disease, a tumor size # 2 cm, and with a positive hormonal 
status. Taking into account this classification, in our study 
most of the low-risk patients (87%) did not present vascular 
invasion, whereas MUC1 apical expression was found in 
25% of them. Vascular invasion-positive tumors did not 
show MUC1 apical reaction at all. This would be related to 
a defective MUC1 pathway that is associated with lack of 
functional differentiation and worse prognosis.19
It is considered that MUC1 is one of the molecules 
bearing the epitope sialyl Lewis x in cancer cells,38 as 
well as other carbohydrate epitopes such as Lewis x and 
Lewis y.39 In this report, a positive correlation between 
MUC1 versus Lewis x (r = 0.8830; P , 0.05) was found 
and also a tendency between MUC1 and Lewis x apical 
expression. These results indicate that MUC1 and Lewis x 
would be coexpressed, which would suggest that this mucin 
may be a Lewis x carrier. In accordance with Brooks and 
Leathem,40 we have detected a higher Lewis x expression in 
normal and benign samples than in breast cancer samples. 
Table 6 Logistic regression analysis for patients and controls 
(normal and BBD) considering risk factors.
Risk and prognostic 
factors
Normal vs malignant 
P (ORR CL)
BBD vs malignant 
P (ORR CL)
Age (years) 0.020; 128 
(2.80–61873)a
0.054; 3.49 
(0.947–362)
Number of children 0.973; 0.956 
(0.069–13.1)
0.246; 20.3 
(0.200–526)
Breastfeeding 0.656; 0.392 
(0.006–24.2)
0.389; 0.199 
(0.015–5.11)
Menopausal age (years) 0.115; 10.1 
(0.567–179)
0.276; 0.527 
(0.381–29.1)
Menarche age (years) 0.553; 2.98 
(0.081–110)
0.742; 0.697 
(0.098–26.2)
Note: aIndicates significant regression P , 0.05.
Abbreviations: BBD, benign breast disease; OR, odds ratio; ORR CL, odds ratio 
range confidence level for ±95% range.
This result was expected because normal samples were 
obtained from women who had had plastic surgery.
Discussion
Breast cancer studies by area can provide important clues to 
the underlying factors that influence the biological behavior 
of this disease. This knowledge would be useful to plan 
interventions and may serve to define indicators for preven-
tive strategies.
It has been largely described that MUC1 may behave 
as an oncoprotein. Almost all breast cancer expresses this 
mucin, although normal breast cells express MUC1 as well. 
Due to the structural complexity of the MUC1 glycoprotein, 
multiple epitopes can be detected by monoclonal antibodies.29 
In this study we found a direct relationship between the 
percentage of MUC1-positive responses in respect of tumor 
size, between RI with disease stage, and also between the 
percentage of positive area and nuclear grade. Coincident 
with these results we found a significant decrease on MUC1 
apical expression frequency according to histological as well 
as nuclear grade increment. Rakha et al30 pointed out that 
histological grade can accurately predict tumor behavior. 
Rahn et al19 reported that aberrantly localized MUC1 in the 
tumor cell cytoplasm or nonapical membrane is associated 
with a worse prognosis. The presence of apical membrane 
staining would indicate that MUC1 targeting pathways 
are intact, and it has been associated with better prognosis 
possibly related to functional differentiation of the tumor.30 
Rahn et al19 found a significantly lower mean nuclear grade 
in tumors with high MUC1 expression (.50%). Our results 
showed a positive relationship between vascular invasion 
and Nottingham Prognostic Index (P , 0.05), and poorly 
differentiated tumors had higher rates of vascular invasion 
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In all cases, we observed a strong, mainly apical, staining, 
although no association with histological grade was found. 
However, Lewis x showed a higher percentage of reactive 
area in more differentiated tumors (P , 0.05). Brooks and 
Leathem40 found Lewis x expression to be associated with 
invading tumor areas, whereas Elola et al41 confirmed that 
MCF-7 cancer cells binding to HUVEC partially depended 
on Lewis x epitopes.
Overexpression of Lewis y antigen has frequently been 
found in human cancers42 and has been observed to be 
associated with poor prognosis.43 Our results showed that 
the percentage of Lewis y-positive responses increased 
according to tumor size increment (P , 0.05) with different 
patterns, and many positive samples showed a linear 
expression. Basu et al44 observed Lewis y at the plasma 
membrane either as a glycolipid or glycoprotein or linked to 
surface receptors, such as epidermal growth factor receptors. 
On the other hand, Klinger et al45 showed that two anti-
Lewis y antibodies inhibited the ErbB-induced stimulation 
of downstream signalling by intracellular rerouting of 
internalized EGF receptors.
Tn and TF are early stage-specific differentiation and 
carcinoma-associated antigens that are related to alterations 
on mucin type O-linked glycosylation and often result in 
shorter glycan chains.31 In accordance to other authors,46 our 
results showed that TF and Tn antigens were expressed in 
hyperplastic benign diseases and also that, in cancer, their 
expression showed a positive association with disease stage. 
Furthermore, the percentage of positive responses augmented 
in relation to increased tumor size. Employing multivariate 
analysis, Tsuchiya et al7 found that Tn expression correlated 
significantly with tumor size, nodal status, and overall 
survival. Although it has been suggested that Tn and TF 
antigens may constitute cancer prognostic factors and that 
they may play significant roles in cancer development, their 
implications need further investigation.
In this study we analyzed several parameters related 
to hormonal aspects and antigenic expression. In this 
sense, we found a significant correlation between MUC1 
RI and ER status. This positive correlation was found in 
the  majority of studies previously published, although 
considering other parameters such as the percentage of 
tumor cells.16 Furthermore, subgroup analysis according 
to hormone receptor (ER and PR) and antigenic expression 
showed that ER-positive and PR-positive groups presented 
higher MUC1 RI than ER-negative and PR-negative 
groups (statistically different). It is known that ER-positive 
tumors have better prognosis than negative ones, and 
almost all tumors expressed MUC1. There is evidence that 
steroid hormones play a role in MUC1 gene and protein 
 expression. In this sense, McGuckin et al47 found that pro-
gesterone caused significant increases in cells and secreted 
MUC1 in breast cancer cell lines. Moreover, in MCF7 cells, 
Ren et al48 concluded that estradiol treatment resulted in a 
gradual increase in MUC1 mRNA expression. Our results 
showed that with breastfeeding and when a patient had at 
least one child, MUC1 expression increased. Also, with 
breastfeeding, antigens involved in tumor dissemination 
here studied diminished their expression, although their 
apical pattern increased, suggesting a more differentiated 
phenotype. It is very interesting that our PCA analysis 
including RI of MUC1 and glycan antigenic expression 
and ER and PR separated a group of patients who were 
characterized by their low age, premenopause status, less 
differentiated tumors, and more advanced disease stages. 
In this analysis, which explained 59% of data variability, 
menopause status appeared as a relevant factor, because 
premenopause patients showed less differentiated tumors. 
When ER and PR were included in this study, premeno-
pause patients with the lowest values were separated. It is 
considered that exposure of ovarian hormones throughout 
life affects the risk of developing breast cancer. A meta-
analysis of 47 epidemiological studies conducted in 30 
countries concluded that the relative risk of breast cancer 
decreased by 4.3% (95% confidence interval 2.9–5.8; 
P , 0.00001) for every 12 months of breastfeeding in 
addition to a decrease of 7.0% (5.0–9.0; P , 0.0001) for 
each birth.49
Tumor cell membrane immunoreactivity for c-erbB2 
(Her2-neu) is associated with poorer survival and is more 
frequently seen in Grade III tumors.50 In our analysis, the 
Her2-neu+ subgroup presented a large number of positive 
nodes, less differentiated tumors, and higher nuclear grades 
than in the Her2-neu negative subgroup. Furthermore, it is 
interesting that Her2-neu+ status showed a significant asso-
ciation with sialyl Lewis x expression.
The interpretation of breast cancer incidence and mortal-
ity patterns is complex in view of the numerous and interac-
tive known and putative risk determinants. In this sense, our 
results emphasize that the carbohydrate antigenic relationship 
with risk and prognostic factors contributes to explain breast 
cancer biological heterogeneity.
The relationship between the carbohydrate antigens 
selected and risk factors such as breastfeeding and number 
of children in this malignancy is of special significance, as 
these factors have been associated with breast protection. The 
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panel of antigens studied has been related to tumor progres-
sion and dissemination.
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